KCM
BEAM icon

Kynam Capital Management’s Beam Therapeutics BEAM Stock Holding History

Kynam Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-937,000
Closed -$26M – 40
2025
Q4 		$26M Buy
+937,000
New +$23.9M 1.66% 18

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Kynam Capital Management's BEAM Position: Q2 2026 in Review

Kynam Capital Management reduced its Beam Therapeutics (BEAM) stake by 23% in Q2 2026, selling an estimated $25.4M and leaving 2,840,792 shares worth $97.5M. The position accounts for 5.39% of the portfolio, ranked #8.

Kynam Capital Management first reported a position in BEAM in Q3 2024 and has held it in 8 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Kynam Capital Management held 2,840,792 shares of Beam Therapeutics worth $97.5M as of Q2 2026.
  • Kynam Capital Management sold 841,393 Beam Therapeutics shares in Q2 2026, an estimated $25.4M.
  • Beam Therapeutics made up 5.39% of Kynam Capital Management's portfolio in Q2 2026, its #8 holding.
  • Kynam Capital Management first reported a position in Beam Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.